

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.</p> <p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p>Sheet 1 of 1</p>		<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>09/430,966</td> </tr> <tr> <td>Filing Date</td> <td>11/01/1999</td> </tr> <tr> <td>First Named Inventor</td> <td>BART DE CORTE</td> </tr> <tr> <td>Group Art Unit</td> <td>1624</td> </tr> <tr> <td>Examiner Name</td> <td>VENKATARAMAN BALASUBRAMANIAN</td> </tr> <tr> <td>Attorney Docket Number</td> <td>JAB 1425</td> </tr> </table>	Application Number	09/430,966	Filing Date	11/01/1999	First Named Inventor	BART DE CORTE	Group Art Unit	1624	Examiner Name	VENKATARAMAN BALASUBRAMANIAN	Attorney Docket Number	JAB 1425
Application Number	09/430,966													
Filing Date	11/01/1999													
First Named Inventor	BART DE CORTE													
Group Art Unit	1624													
Examiner Name	VENKATARAMAN BALASUBRAMANIAN													
Attorney Docket Number	JAB 1425													

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov, or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Docket No. JAB 1425

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bart DE CORTE et al.

Serial No. : 09/430,966 Art Unit: 1624

Filed : 11/01/1999
BALASUBRAMANIAN

Examiner: VENKATARAMAN

For : HIV REPLICATION INHIBITING PYRIMIDINES

I hereby certify that this correspondence is being transmitted via facsimile to:
Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

January 23, 2004

(Date of Deposit)

Jesús Juanós i Timoneda

(Name of applicant, assignee, or Registered Representative)

January 23, 2004

(Date of Signature)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the First Information Disclosure Statement mailed on August 11, 2003.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with \$1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in \$1.17(p).

☐ In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: References contained in form 1449 which are not enclosed in this facsimile will be sent as hard copies to the Examiner.

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB 1425/JJiT. This form is submitted in triplicate.

Respectfully submitted,



Jesus Guano i Timoneda
Reg. No. 43,332
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1513
DATED: January 23, 2004